VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SIBNSI-BONE, Inc.
$17.33$769M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSIBNBalance Sheet

SI-BONE, Inc. (SIBN) Balance Sheet

13Y historyFree accessUpdated daily

The company has successfully improved its financial flexibility by reducing total debt from $39.0 million in 2023Q4 to $7.3 million in 2026Q1.

SIBN Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Total Current Assets214.72M216.12M207.78M211.39M137.61M175.87M218.24M111.46M136.04M33.63M36.32M29.9M26M16.47M
Cash & Short-Term Investments144.68M147.82M150.04M166.02M97.29M146.98M196.43M91.78M122.22M22.41M27.9M20.27M17.6M8.52M
Cash Only33.53M42.24M34.95M33.27M20.72M63.42M53.58M10.44M25.12M22.41M27.9M20.27M17.6M8.52M
Short-Term Investments111.15M105.58M115.09M132.75M76.57M83.56M142.85M81.34M97.1M00000
Accounts Receivable30.96M29.91M27.46M21.95M20.67M14.25M13.61M11.72M8.49M7.42M5.95M5.77M5.88M6.04M
Days Sales Outstanding49.4654.3459.9557.6970.9257.6867.763.5655.9356.4151.5951.1453.5644.97
Inventory35.53M33.9M27.07M20.25M17.28M11.5M5.63M5.45M3.34M2.55M1.51M2.7M1.69M1.26M
Days Inventory Outstanding302.18301.42281.88250.83401.65402.45230.96293.08252.47182.29106.99182.5794.62106.08
Other Current Assets3.54M4.48M3.2M3.17M2.37M0001.99M001.16M837K655K
Total Non-Current Assets28M22.44M22.66M19.03M19.94M14.64M4.9M5.55M2.48M2.21M3.11M6.16M2.99M1.54M
Property, Plant & Equipment27.78M22.39M22.36M18.71M19.57M14.24M4.53M3.95M2.15M1.9M2.61M3.53M2.61M1.2M
Fixed Asset Turnover8.55x8.98x7.48x7.42x5.44x6.33x16.21x17.02x25.71x25.31x16.14x11.65x15.36x40.83x
Goodwill00000000000000
Intangible Assets0000000007.42M47K55K62K70K
Long-Term Investments00000001.28M00521K634K00
Other Non-Current Assets217K55K300K325K375K400K374K315K325K269K457K1.93M319K274K
Total Assets242.72M238.56M230.44M230.43M157.55M190.51M223.14M117.01M138.52M35.83M39.44M36.05M28.98M18.01M
Asset Turnover0.87x0.84x0.73x0.60x0.68x0.47x0.33x0.58x0.40x1.34x1.07x1.14x1.38x2.72x
Asset Growth %16.68%3.52%0.01%46.25%-17.3%-14.63%90.7%-15.53%286.56%-9.13%9.38%24.39%60.9%-
Total Current Liabilities21.49M25.28M27.13M23.46M21.18M16.89M13.47M18.77M9.01M7.54M13.39M6.81M6.94M10.21M
Accounts Payable6.76M4.63M6.49M4.59M6.28M3.2M3.27M2.81M2.15M1.81M1.02M2.49M2.6M3.73M
Days Payables Outstanding57.6841.1867.5556.83145.93111.94134.12151.11162.07129.5272.43168.64146.28314.61
Short-Term Debt658K944K000004.36M008.24M002.22M
Deferred Revenue (Current)00000000003.91M000
Other Current Liabilities14.07M19.7M14.85M15.16M12.34M11.36M9.69M8.01M5.56M1.53M3.06M4.32M4.34M4.25M
Current Ratio9.99x8.55x7.66x9.01x6.50x10.41x16.20x5.94x15.11x4.46x2.71x4.39x3.74x1.61x
Quick Ratio8.34x7.21x6.66x8.15x5.68x9.73x15.78x5.65x14.73x4.12x2.60x3.99x3.50x1.49x
Cash Conversion Cycle293.96314.58274.28251.69326.64348.19164.54205.53146.33109.1886.1565.071.89-163.56
Total Non-Current Liabilities42.29M35.74M36.34M37.59M38.07M39.2M40.31M35.23M39.32M157.67M134.78M26.01M15.15M9.46M
Long-Term Debt6.69M175K35.45M36.06M35.17M34.97M39.45M34.87M38.96M38.7M21.07M25.06M15.15M9.46M
Capital Lease Obligations483K0879K1.51M2.87M4.17M00000000
Deferred Tax Liabilities00000000000000
Other Non-Current Liabilities35.6M35.57M10K18K30K57K854K362K360K118.97M113.71M957K-15.15M-9.46M
Total Liabilities63.78M61.02M63.47M61.05M59.25M56.09M53.78M54M48.33M165.21M148.17M32.82M22.09M19.67M
Total Debt7.35M1.12M37.48M38.99M39.43M40.48M39.45M39.22M38.96M38.7M29.31M25.06M15.15M11.68M
Net Debt-26.19M-41.12M2.54M5.72M18.71M-22.94M-14.13M28.79M13.84M16.3M1.41M4.78M-2.45M3.17M
Debt / Equity0.04x0.01x0.22x0.23x0.40x0.30x0.23x0.62x0.43x--7.75x2.20x-
Debt / EBITDA-0.62x-------------
Net Debt / EBITDA2.22x-------------
Interest Coverage-6.06x-2.58x-7.99x-11.52x-20.73x-9.89x-6.16x-6.76x-2.42x-2.71x-5.22x---
Total Equity178.94M177.53M166.96M169.38M98.3M134.42M169.36M63.01M90.19M-129.38M-108.73M3.23M6.89M-1.65M
Equity Growth %21.05%6.33%-1.42%72.3%-26.87%-20.63%168.8%-30.14%169.71%-18.99%-3463.22%-53.09%516.94%-
Book Value per Share4.074.084.034.412.874.065.832.555.67-9.33-7.020.132.58-0.72
Total Shareholders' Equity178.94M177.53M166.96M169.38M98.3M134.42M169.36M63.01M90.19M-129.38M-108.73M3.23M6.89M-1.65M
Common Stock4K626.97M4K4K3K3K3K3K3K1K1K7K5K4K
Retained Earnings-454.59M-450.26M-431.35M-400.44M-357.11M-295.85M-239.28M-195.58M-157.18M-139.72M-116.69M-96.1M-67.94M-40.14M
Treasury Stock000000000-9.94M-8.01M000
Accumulated OCI501K816K244K335K232K352K524K464K439K402K472K405K-498K-249K
Minority Interest00000000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Persistent Operating Cash Burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Capital Base Stability Amid Losses

According to historical balance sheet data, SIBN has maintained a relatively stable equity base of approximately $178.9 million as of 2026Q1, despite accumulating losses that have pushed retained earnings to negative $454.6 million, signaling a reliance on external capital to sustain its ongoing operational expansion.

The company's ability to preserve its equity position despite persistent net losses suggests that previous capital raises have provided a sufficient buffer to fund operations. However, the widening deficit in retained earnings warrants close monitoring, as it indicates that the business model has not yet reached the scale required to generate self-sustaining internal growth.

Strategic Deleveraging Enhances Financial Flexibility

As reported in recent financial statements, SIBN has aggressively reduced its total debt from $39.0 million in 2023Q4 to just $7.3 million by 2026Q1, reflecting a deliberate shift toward a cleaner balance sheet that minimizes interest expense during this critical phase of market penetration.

This rapid deleveraging appears to be a strategic move to reduce financial risk while the company continues to navigate its path toward profitability. By minimizing debt obligations, management has effectively lowered the company's break-even threshold, which may provide greater flexibility to weather potential volatility in elective procedure volumes.

Robust Liquidity Buffers Operational Volatility

Based on the most recent quarterly filings, SIBN maintains a current ratio of 9.99, which provides a substantial liquidity cushion that appears more than adequate to cover short-term liabilities and support the company's ongoing investment in its specialized sales force and clinical education infrastructure.

The exceptionally high current ratio suggests that the company is well-positioned to manage its working capital requirements without immediate liquidity concerns. Investors should note that while this liquidity is a strength, it also reflects a significant amount of capital tied up in current assets, which may require more efficient management as the company matures.

Inventory Risks in Consignment Model

Analysis of the balance sheet reveals that PPE and other assets are growing, yet the lack of detailed inventory disclosures in the provided data suggests that the company's reliance on a consignment-heavy model may hide potential obsolescence risks as newer product generations like iFuse-TORQ gain traction.

The transition to newer product platforms often necessitates the write-down of older inventory held at hospitals, which could create unexpected charges against future earnings. Analysts should remain cautious regarding the quality of these assets, as the true value of consignment inventory is often subject to management's judgment regarding product lifecycle and demand.

SIBN — Frequently Asked Questions

Quick answers to the most common questions about buying SIBN stock.

What are the total assets of SI-BONE, Inc. (SIBN)?

As of 2025, SI-BONE, Inc. (SIBN) had total assets of $238.6M including $216.1M in current assets.

How much debt does SI-BONE, Inc. (SIBN) have?

SI-BONE, Inc. (SIBN) carries total debt of $1.1M, offset by $147.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of SI-BONE, Inc.?

SI-BONE, Inc. (SIBN) has total shareholders' equity (book value) of $177.5M ($4.08 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is SI-BONE, Inc.'s current ratio and liquidity?

SI-BONE, Inc. (SIBN) reported a current ratio of 8.55x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.